What makes us different from other trading websites and investment newsletters?
Value. Your monthly subscription costs about as much as you pay your broker for one or two option trades.
Accountability. Unlike other sites, we don't just drop trades and walk away. Phil Davis, David Ristau and Optrader are on-line most trading days to talk to you live. How's that for backing up our trade ideas? We follow our trades through from open to close and we're there for you to help analyze your own trades and look for ways to improve them.
Exclusivity. You can’t make trades with 10,000 other people - it just doesn’t work! We limit our membership to give everyone a chance to pick up the positions we spot.
Community. Come for the great calls…stay for the great conversation. Our active daily forum is unique – no other investment newsletter or trading service has such a busy community of informed members offering their own opinions, ideas, and input.
Phil is often an active participant, not just a name on the marquee. If you’re an amateur or professional trader, you’ll find that our members are some of the smartest and most experienced around. No matter who you are, you’ll benefit from the dialogue our subscribers have with each other every single day.
A message from Phil:
There’s nothing I hate more than people who tell you what you would have made if you had done some perfect entry and perfect exit on a trade they vaguely recommended out of dozens that didn’t work out. It’s never going to happen here!
We keep a running archive of every single post and ever single trade idea since November of 2005 so you can see for yourself what you think of our picks! Do I need your credit card so you can look? No, why should I - the work should stand on their own. If you think they would have helped you in the past then you may decide on your own whether you want to sign up for our daily live site.
How can we give all that away for free? Because our performance is not a fluke, we do this all the time and we’re pretty sure there will be brand new trading opportunities for us tomorrow - the old ideas you can keep with our compliments!
This is not your run-of-the-mill dry, financial reporting! According to Google, there are 11,500,000 stock picking pages on the web and they all think they’re smarter than us… We don’t try to out shout the masses - we just try to have some fun and make some money! Now I’ve been told by marketing experts that I need to put in giant letters that say we make more trades, more often than most newsletters (we do), that I should make a big deal about how we try to pick real, well-known companies that are fairly liquid so you can get your money in and (more importantly) out and I’m supposed to make a big deal about beating the markets month after month (we do). I’m not going to do that...
When I used to look for a financial newsletter I would always read that stuff and go “blah blah blah” in my head until I found some kind of sample of the actual trading. Well, we give you full access to our posted trade ideas and, when you sign up for a FREE trial of the PSW report, you can even view EVERY SINGLE comment and trade idea in our premium member chat from the past 7-30 days. All the winners and all the losers, not just selected “samples”. There’s also a weekly update free, right on this site and you can take a look most Fridays or Saturdays for yourself and you can check out my style for yourself and decide if it would annoy or please you to read me every day.
All right, so I’m not good at marketing - but that’s not why you’re here is it? I am an amateur investor, like you, who just got sick of all the BS I was getting from all the “professional” services and I decided to start my own. I’m not a broker or a pro trader and you would be nuts to make any trade you read about here without consulting a professional financial advisor as to its suitability for your virtual portfolio… But, if you like to talk about stocks and pick up some tips that might work without all the hype and nonsense - come join us!
So why listen to me? I do have sort of a knack for spotting trends and picking winners and I’m happy to share what I know with you. No other reason. Nothing bad will happen to you if you don’t sign up with us - there is no pressure and this is not a limited offer. Come back any time we are accepting new members - the door will always be open. Looking forward to meeting you, - Phil
Help One Of Our Own PSW Members
May 22nd, 2014 5:03 pm
"Hello PSW Members –
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at email@example.com with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
As if Ukraine was not struggling through enough turmoil currently, Bloomberg reports that the fragile coalition government has collapsed after two parties quit. The UDAR and Svoboda parties said they’d leave the government and seek a snap parliamentary ballot. Tempers have been fraying recently as numerous brawls have broken out in parliament ahead of President Poroshenko's pledge to call elections this year. All we have to do now is find out who Washington would like to see in power? The end result: Prime Minister Yatsenyuk just resigned. The bi...
Advisor Perspectives welcomes guest contributions. The views presented here do not necessarily represent those of Advisor Perspectives.
The BCI at 179.2 is up from last week’s 178.5. The BCIg, the smoothed annualized growth of BCI, at 22.2 is at its highest level in the current business cycle, rising from last week's 21.6. This week’s BCI does not indicate a possible recession in the near future.
Figure 1 plots BCIp, BCI, BCIg and the S&P500 together with the thresholds (red lines) that need to be crossed to be able to call a recession. Figure 2 plots the history of BCI, BCIg, and the LOG(S&P500) since July 1967, i.e. the last 44 years which include seven recessions, each which the BCI managed to indicate timely.
Steel giant ArcelorMittal (NYSE: MT) has completed the divestment of its 78% stake in European port handling and logistics company ATIC Services S.A. (ATIC) to HES Beheer for €155.4 million (roughly $213 million).
With this transaction, HES Beheer now owns 100% stake in ATIC where it previously held 22% stake. The transaction reflects ArcelorMittal`s strategy of selective deposal of non-core assets.
ArcelorMittal posted a net loss of $0.2 billion or 12 cents per share in first-quarter 2014, narrower than a net loss of $0.3 billion or 21 cents a year ago.
Revenues inched up 0.2% year over year to $19.8 billion in the reported quarter. Sales were almost unchanged from the prior quarter as improved steel shipments were partly offset by lower...
A large call spread initiated on Orexigen Therapeutics, Inc. (Ticker: OREX) on Monday morning looks for shares in the name to rally approximately 30% by September expiration. The September expiration is noteworthy as the company awaits the results of the FDA’s review of its resubmitted New Drug Application (NDA) for NB32, an investigational medication being evaluated for weight loss, after the review was extended for three months back in June. The upcoming Prescription Drug User Fee Act (PDUFA) date is September 11, 2014, according to a press release issued by the company. Shares in Orexigen today are up roughly 0.40% at $5.34 as of 2:15 p.m. ET.
Despite a highly eventful week in the news, not much has changed from a stock market perspective. No doubt, investors have grown immune to the daily reports of geopolitical turmoil, including Ukraine vs. Russia for control of the eastern regions, Japan’s dispute with China over territorial waters, Sunni vs. Shiite for control of Iraq, Christians being driven out by Islamists, and other religious conflicts in places like Nigeria and Central African Republic. But last Thursday’s news of the Malaysian airliner tragically getting shot down over Ukraine, coupled with Israel’s ground incursion into Gaza, had the makings of a potential Black Swan event, which in my view is the only thing that could derail the relentless bull march higher in stocks.
Nevertheless, when it became clear that the airline...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
We tried holding up stock prices but couldn’t get the job done. Market Shadows’ Virtual Value Portfolio dipped by 2% during the week but still holds on to a market-beating 8.45% gain YTD. There was no escaping the downdraft after a major Portuguese bank failed. Of all the triggers for a large selloff, I’d guess the Portuguese bank failure was pretty far down most people's list of "things to worry about."
All three major indices gave up some ground with the Nasdaq composite taking the hardest hi...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
I just wanted to be sure you saw this. There’s a ‘live’ training webinar this Thursday, March 27th at Noon or 9:00 pm ET.
If GOOGLE, the NSA, and Steve Jobs all got together in a room with the task of building a tremendously accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.
Well, I hate to break it to you though… they never got around to building it, but my friends at Market Tamer did.
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.